Mayo Clinic Cancer Center Neuro-Oncology Program Registry and Biobank for the Study of Nervous System Tumors

Overview

About this study

Biospecimen banks are a modern attempt to centralize collections of human blood and tissue samples along with health information and personal history. The Neuro-Oncology Program Registry and Biobank will be used for research purposes to increase our understanding of nervous system tumors.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

All adult and pediatric patients with a type of nervous system tumor included in a list of histopathologies will be eligible to enroll in the Neuro-Oncology Program Registry and Biobank. This list may be modified in the future. The current list includes:
- Astrocytoma;
- Dysembryoplastic Neuroepithelial Tumor;
- Ependymoma;
- Ganglioglioma;
- Glioma;
- Gliosarcoma;
- Medulloblastoma;
- Meningioma;
- Mixed Oligodendroglioma-Astrocytoma;
- Oligodendroglioma;
- Pilocytic Astrocytoma;
- Pleomorphic Xanthoastrocytoma;
- Schwannoma;
- Subependymal Giant Cell Astrocytoma;
- Subependymoma;
- Primitive neuro-ectodermal tumors;
- Vitreoretinal Lymphoma (adult subjects only);
- Primary CNS lymphoma;
- Brain metastases including, but not limited to, melanoma, breast, lung and renal cancers;
- Pineal region tumors;
- Germ cell tumors;
- Hemangiopericytoma;
- Diffuse Intrinsic Pontine Glioma (DIPG);
- Intracranial solitary fibrous tumors;
- Neurofibroma;
- Primary spine tumors including sarcoma;
- Metastases to the spine and spinal canal;
- Chordoma and Chondrosarcoma of the sacrum, spine, or skullbase.
- Pituitary Adenomas or pituitary pathology (SCO etc).
- Craniopharyngiomas.
- Chondrosarcomas.
- Meningiomas.
- Solitary Fibrous Tumors.
- Glomus tumors.
- Esthesioneuroblastoma.
- Anterior Skull Base malagnancies: adenoid cystic, squamous cell and adenocarcinoma of the nasal cavity.

Exclusion Criteria:

Patients with a histopathology other than that listed above.
Patients whose pathologic diagnosis cannot be confirmed will not be eligible to enroll in the Neuro-Oncology Program Registry and Biobank.
Excluding participants from the MRI component of the study if they have a clinical contraindication that would prevent them from safely completing the MRI.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/14/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Jann Sarkaria, M.D.	Open for enrollment	Contact information: Michelle Bublitz M.H.A., CCRP (507) 284-8172 Bublitz.Michelle@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jann Sarkaria, M.D.

Open for enrollment

Contact information:

Michelle Bublitz M.H.A., CCRP

(507) 284-8172

Bublitz.Michelle@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials